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ATF3 Expression in the Corpus Luteum: Possible Role
in Luteal Regression†
Dagan Mao, Xiaoying Hou, Heather Talbott, Robert Cushman, Andrea Cupp, and
John S. Davis
Research Service (J.S.D.), Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha,
Nebraska 68105 Olson Center for Women’s Health (D.M., X.H., J.S.D.), Department of Obstetrics and
Gynecology, and Department of Biochemistry and Molecular Biology (H.T., J.S.D.), University of
Nebraska Medical Center, Omaha, Nebraska 68198; College of Animal Science & Technology (D.M.),
Nanjing Agricultural University, Nanjing, Jiangsu 210095, China; United States Department of
Agriculture, United States Meat Animal Research Center (R.C.), Clay Center, Nebraska 68933; and
Department of Animal Science (A.C.), University of Nebraska-Lincoln, Lincoln, Nebraska 68583
The present study investigated the induction and possible role of activating transcription factor 3
(ATF3) in the corpus luteum. Postpubertal cattle were treated at midcycle with prostaglandin
F2(PGF) for 0–4 hours. Luteal tissue was processed for immunohistochemistry, in situ hybridiza-
tion, and isolation of protein and RNA. Ovaries were also collected from midluteal phase and
first-trimester pregnant cows. Luteal cells were prepared and sorted by centrifugal elutriation to
obtain purified small (SLCs) and large luteal cells (LLCs). Real-time PCR and in situ hybridization
showed that ATF3 mRNA increased within 1 hour of PGF treatment in vivo. Western blot and
immunohistochemistry demonstrated that ATF3 protein was expressed in the nuclei of LLC within
1 hour and was maintained for at least 4 hours. PGF treatment in vitro increased ATF3 expression
only in LLC, whereas TNF induced ATF3 in both SLCs and LLCs. PGF stimulated concentration- and
time-dependent increases in ATF3 and phosphorylation ofMAPKs in LLCs. Combinations ofMAPK
inhibitors suppressed ATF3 expression in LLCs. Adenoviral-mediated expression of ATF3 inhibited
LH-stimulated cAMP response element reporter luciferase activity andprogesteroneproduction in
LLCs and SLCs but did not alter cell viability or change the expression or activity of key regulators
of progesterone synthesis. In conclusion, the action of PGF in LLCs is associated with the rapid
activation of stress-activated protein kinases and the induction of ATF3, which may contribute to
the reduction in steroid synthesis during luteal regression. ATF3 appears to affect gonadotropin-
stimulated progesterone secretion at a step or steps downstream of PKA signaling and before
cholesterol conversion to progesterone. (Molecular Endocrinology 27: 2066–2079, 2013)
The corpus luteum, a transient endocrine gland formedfrom the ovarian follicle after ovulation, plays an
important role in the regulation of normal reproductive
cycles and in the maintenance of pregnancy. In the
absence of pregnancy, the corpus luteum undergoes the
degenerative process of regression or luteolysis. As a
result of the luteolytic process, a new reproductive cy-
cle ensues. Luteolysis is characterized by the rapid ces-
sation of progesterone production (functional regres-
sion) followed by involution of the corpus luteum
glandular structure via apoptotic death (structural re-
gression) (1, 2). Prostaglandin F2 (PGF), a major lu-
teolytic factor, was identified more than 40 years ago in
mammals (3), but the cellular mechanisms by which
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PGF initiates the luteolytic cascade remain poorly
understood.
Luteinized follicular cells acquire the capacity to re-
spond to PGF through increased expression of the Gq-
coupled prostaglandin F receptor (PTGFR). It is well
known that activation of the PTGFR rapidly induces cal-
cium mobilization and activation of protein kinase C
(PKC) (4). These initial events lead to activation ofMAPK
signaling cascades including ERK1/2 (5, 6), p38, and c-
Jun N-terminal kinase (JNK) (7, 8) in vivo and in vitro,
with subsequent activation of multiple transcription fac-
tors. These signaling pathways, particularly activated
MAPK signaling, are involved in inducing a rapid and
dramatic increase in the immediate early genes such as
FOS and JUN (9, 10), NR4A1 (11, 12), and EGR1 (11,
13) in the corpus luteum. Recent studies demonstrate that
PGF treatment induces global changes in gene expression
in corpus luteum, including immediate early genes, ste-
roidogenic genes, prostaglandin-related genes, immune-
related genes, and angiogenesis-related genes (11,
14–18).
Activating transcription factor 3 (ATF3) is a member
of the activating transcription factor/cAMP responsive
element binding (CREB) protein family of transcription
factors. The basal level ofATF3mRNA is typically low or
undetectable in most tissues and cell lines, but greatly
increases under stress conditions, and is considered to be
an adaptive-response gene (19, 20). Extracellular signals
including cytokines, chemokines, growth factors/hor-
mones, or DNA damage can induce ATF3 expression
(21). This protein binds the cAMP response element
(CRE) and may repress transcription by stabilizing the
binding of inhibitory cofactors at the promoter (19, 22).
Target genes of ATF3 have been reported to associate
with metabolism (23–25), differentiation (26), inflamma-
tion (27, 28), survival, and apoptosis (29, 30) in multiple
cell types. ATF3 is one of the immediate-early response
genes in vascular endothelial cells in response to athero-
genic stimuli and may play a role in the endothelial cell
death (31, 32). ATF3 has been implicated as a regulator in
host defense against invading pathogens and as a tumor
suppressor in various forms of cancer (22, 33).
Mondal et al (34) found that PGF treatment increased
ATF3 protein expression in the bovine corpus luteum,
rendering the hypothesis that ATF3 may induce changes
in luteal function associated with luteolysis. Many signal-
ing pathways have been demonstrated to be involved in
the induction of ATF3 by stress signals, including the
JNK, p38, nuclear factor-B (NFB), PKC, and calcium
signal pathways (21). However, the mechanism of induc-
tion and the function of ATF3 in the corpus luteum are
unknown. In this report, we found that PGF induced
ATF3 mRNA and protein expression in corpora lutea
from midcycle cows in vivo and in luteal cells isolated
from both midcycle and pregnant corpora lutea in vitro.
We found that PGF selectively induced a concentration-
and time-dependent increase in ATF3 expression in large
luteal cells (LLCs), whereas TNF- stimulated ATF3 ex-
pression in small luteal cells (SLCs) and LLCs. To begin to
understand the role of ATF3 in luteal cells, we expressed
ATF3 using an adenoviral construct. We found that ex-
pression of ATF3 reduced LH-stimulated CRE-depen-
dent transcription of a luciferase promoter reporter and
progesterone synthesis in both SLCs and LLCs, but did
not alter the viability of LLCs or SLCs. The induction of
ATF3, therefore, may serve to modulate gonadotropin
responsiveness during luteolysis.
Materials and Methods
Reagents
PGF, protease and phosphatase inhibitor cocktails, 22R-hy-
droxycholesterol (22R-OH-CH), 4,6-diamidino-2-phenylin-
dole, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), hydrogen peroxide, and hematoxylin were
from Sigma. Human TNF- and Fas ligand were from R&D.
Bovine IGF-1 was from GroPep. The MEK1/2 inhibitor
(U0126) was from Enzo. The p38 MAPK inhibitor (SB203580)
and JNK inhibitor (SP600125) were from EMD Millipore. Bo-
vine LH was purchased from Tucker Endocrine Research Insti-
tute. M199 was from Lonza. Fetal bovine serum (FBS) was
obtained from Valley Biomedical. Penicillin-streptomycin and
Gentamycin were from Gibco, and Amphotericin B was from
MP Biomedical, LLC. Type II collagenase was obtained from
Atlantic Biologicals. The unmasking solution, antirabbit VEC-
TASTAIN ABC kit, 3,3diaminobenzidine detection kit, and
VectaMount were obtained from Vector Laboratories. All anti-
bodies were from Cell Signaling Technology except for ATF3
(Santa Cruz Biotechnology), SR-B1 ( Novus Biological; -actin
and antimouse horseradish peroxidase (HRP)-conjugated IgG
(Sigma); steroidogenic acute regulatory protein (StAR) (abcam);
CYP11A1 (Millipore); 3 -hydroxysteroid dehydrogenase
(HSD3B) (a gift fromDr. IanMason); vimentin (Millipore); and
antirabbit HRP-conjugated IgG (Jackson ImmunoResearch
Laboratories, Inc.). The bovine luteal endothelial cell line was
prepared in our laboratory as previously described (35).
Bovine corpus luteum tissue
Postpubertal cattle of composite breeding at midluteal phase
(days 9–10) were injected with saline (n 3) or a luteolytic dose
(25 mg) of the PGF analog Lutalyse (n  9) (Upjohn Co). Ova-
ries were surgically removed from saline-injected controls (0
hours) or at 1, 2, and 4 hours after PGF injection. Luteal tissues
were rapidly dissected from the ovary, sliced, and either snap-
frozen in liquid nitrogen and stored at 80°C for protein and
RNA, or fixed for immunohistochemistry and in situ hybridiza-
tion. All procedures were approved by the University of Nebras-
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ka-Lincoln and University of Nebraska Medical Center Institu-
tional Animal Care and Use Committees.
Isolation of steroidogenic luteal cells
Bovine ovaries were collected from first-trimester pregnant
cows (fetal crown rump length  10 cm) and midcycle cows as
described by Ireland et al (36) at a local slaughterhouse (XL
Four Star Beef, Inc.). Enriched steroidogenic cells were prepared
from the luteal slices by enzymatic digestion with type II colla-
genase as described previously (37, 38).
SLCs and LLCs were separated using a Beckman Coulter
Avanti J-20 XP centrifuge equipped with a Beckman JE-5.0
elutriator rotor. The mixed luteal cells from early pregnant cor-
pus luteum were resuspended and subjected to centrifugal elu-
triation using elutriation medium (calcium-free DMEM (US Bi-
ological; catalog no. D9800–10), 25 mM HEPES, 0.1% BSA,
0.02mg/mL deoxyribonuclease, 3.89 g/L sodium bicarbonate, 3
mg/mL glucose, and antibiotics). The eluateswere collectedwith
continuous flow. The viability, concentration, and size of cells in
each fraction were determined using a hemocytomer and the
trypan blue exclusion test. Cells with a diameter of 15–25 m
were classified as SLCs, and cells with a diameter greater than 30
m were classified as LLCs. A 100 mL fraction (F1) containing
predominantly erythrocytes and endothelial cells ( 10 m)
and a variable degree of SLCs was harvested using a flow rate of
16 mL/min at 1800 rpm. The following 100 mL fraction (F2)
containing predominantly SLCs (1020 m) was harvested
using a flow rate of 16 mL/min at 1400 rpm. A third fraction
(F3) containing small-cell clumps mixed with large cells was
collected using a flow rate of 24 mL/min at 1200 rpm. The
remaining fraction (F4), a highly enriched LLC fraction ( 30
m) containing less than 5% enucleated cells, was collected
using a flow rate of 30 mL/min at 680 rpm. The cells were then
pelleted and resuspended inM199. Cells in F2 and F4 were used
in experiments as reported in the figure legends. The average
purity of SLCs in F2 and LLCs in F4 were 81.6  2.78% and
76.9%  3.77% (n  15).
Cell culture
The cells were seeded at a density of 1  105 cells/cm2 for
mixed cells and SLCs, and a density of 4  104 cells/cm2 for
LLCs. Cells were allowed to attach in a 5% CO2 incubator at
37°C in M199 medium, containing 5% FBS, 0.1% BSA, 100
U/mL penicillin, 100 g/mL streptomycin, 10 g/mL Gentamy-
cin, and 2.5 g/mL Amphotericin B. The next day, media was
removed and cells washed with PBS, after which cells were in-
cubated in serum-free medium overnight. On the day of the
experiment, the medium was replaced with fresh preequili-
brated media, and cells were equilibrated for 2–3 hours before
applying various treatments as described in the legends to the
figures.
Real-time PCR
Total RNA was extracted from corpora lutea using the Ab-
solutely RNAMiniprep Kit (Agilent Technologies) according to
themanufacturer’s directions. Quantification, purity, and integ-
rity of the RNA were verified using a Nanodrop instrument
(Nanodrop Technologies). cDNA was synthesized from 1 g of
total RNA using iScript Reverse Transcription Supermix (Bio-
Rad Laboratories) with a final reaction volume of 20 L fol-
lowing the manufacturer’s recommendations. Primers were de-
signed based on bovine ATF3 and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) cDNA sequences using online primer
3.0 (www.SimGene.com). Quantitative real-time PCRs were
carried out on the CFX96 Real-Time PCR Detection System
(Bio-Rad) using 1 L of prepared cDNA, 250 nM primers, and
10 L of FAST SYBR Green Master Mix with a final reaction
volume of 20 L. Cycling conditions were as follows: 30 sec-
onds at 95°C, and 40 cycles of 95°C for 5 seconds and 60°C for
5 seconds. The amount of specific mRNA was calculated from
the linear portion of the amplification signal. Samples contain-
ing no RNA or RNA without reverse transcriptase were used as
negative controls. The sequences for forward and reverse prim-
ers were as follows: ATF3 (NM_001046193.2): forward, 5-
AGCACCTCTGCCACCGGATGT-3;reverse,5-CTTTCAGG
GGCTACCTCGGCTTT-3. GAPDH (NM_001034034.2):
forward, 5-TCTGCACCTTCTGCCGATG-3; reverse, 5-AG-
CAGTTGGTGGTGCAGGA-3. A melting curve analysis was
performed to ensure a single product was amplified from each
primer pair at a temperature consistent with the expected am-
plification product.
In situ hybridization
Luteal tissue slices were quickly frozen in Optimal Cutting
Temperature compound (OCT) on nitrogen liquid and stored at
80°C until sectioning. Tissues were sectioned 12 m and
placed on superfrost plus slides (VWR Scientific) and stored at
80°C. Tissue sections were sent to Affymetrix, Inc. to detect
ATF3 and GAPDH gene expression by in situ hybridization
using protocol QG ViewRNA-Fresh Frozen Tissue. Briefly,
fresh frozen tissues samples were fixed for 16–18 hours in 4%
formaldehyde at room temperature followed by protease diges-
tion, target hybridization, and signal amplification in which
labeled probe oligonucleotides conjugated to alkaline phos-
phate hybridize to each amplifier molecule. Then Fast Red Sub-
strate was added to form a precipitate (red dots) that indicates
the presence of the target RNA molecule. Finally, sections were
counterstained with Gill’s Hematoxylin.
Western blot analysis
For in vivo tissue samples, corpora lutea were weighed and
then put into Pierce RIPA buffer (Thermo Scientific) with pro-
tease and phosphatase inhibitor cocktails and brought to the
laboratory in dry ice. Tissues were then homologized with tissue
homogenizer (OMNI) and were sonicated for five 2-second
bursts with a cell homogenizer (Sonics &Materials Inc.). For in
vitro samples, luteal cell cultures were harvested into lysis buffer
(20mMTris, 1mMEDTA, 0.2mMEGTA, 150mMNaCl, and
1%Triton X-100 and protease and phosphatase inhibitor cock-
tails). Cells were then lysed by sonication. Lysates were centri-
fuged at 18 350 g for 15 minutes at 4°C, and the supernatant
was collected for SDS-PAGE analysis. Protein concentrations
were determined by protein assay dye reagent (Bio-Rad; catalog
no.500–0006). Aliquots of each sample (40–50 g of protein)
were resolved on 10% SDS-PAGE gels and transferred to nitro-
cellulose membranes. After transfer, the membranes were
blocked in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1%
Tween 20; pH 7.5) with 5% fat-free milk for 1 hour at room
temperature. Membranes were incubated overnight with the
primary antibody diluted in TBST with 5% nonfat milk or BSA
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at 4°C. After three 5-minutes washes with TBST, membranes
were incubated for 1 hour at room temperature with antirabbit
(1:20 000) or mouse (1:2000) HRP-conjugated IgG diluted in
TBST with 5% nonfat milk. After three 5-minute washes,
protein bands were detected with ECL reagent (Thermo Sci-
ence or PerkinElmer). Signals were visualized using x-ray film
or a Kodak Digital Sciences Image Station 440 (Eastman
Kodak). Densitometry was performed using Image J software
(http://rsbweb.nih.gov/ij/).
Immunohistochemistry
Corpora lutea were excised and fixed by immersion in 10%
formalin for 24 hours and then changed into 70% ethanol until
embedded in paraffin. Tissues were cut into 4-m sections and
mounted onto polylysine-coated slides. Slides were deparaf-
finized through 2 changes of xylene and through graded alco-
hols to water. Slides were microwaved in citrate-based unmask-
ing solution (Vector Laboratories) for antigen retrieval.
Endogenous peroxidase was quenched with 0.3% hydrogen
peroxide in methanol for 30 minutes. Sections were incubated
without (negative control) or with anti-ATF3 (1:500) and sub-
sequently an antirabbit VECTASTAIN ABC Kit, and stained
using a 3,3diaminobenzidine detection kit. Slides were coun-
terstained with hematoxylin, dehydrated through graded alco-
hols, and coverslipped with VectaMount.
Fluorescence immunocytochemistry
Bovine luteal cells were cultured in 4-well Lab-Tek glass
chamber slides (Nalge Nunc International). After treatment
with 100 nM PGF for 2 hours, the cells were washed with PBS
and fixedwith 4%paraformaldehyde for 15minutes. Cells were
then blocked with 10% donkey serum, 0.1%Triton X-100, and
0.1% sodium azide in PBS (pH 7.4) for 30 minutes at room
temperature. Sections were then incubated with anti-ATF3 (1:
100) at 4°C in a humidified chamber overnight. Immune reac-
tive proteins were detected by incubating with a Texas red-X
goat antirabbit antibody (1:200, red fluorescence) and Alexa
Fluor 488-conjugated antimouse IgG (1:500, green fluorescence
) for 1 hour at room temperature. Nuclei were stained simulta-
neously with 4,6-diamidino-2-phenylindole (1:100, blue fluo-
rescence). Sections were washed with PBS and then mounted
with Vectashield. Two hours later, sections were examined un-
der epifluorescence in an Olympus instruments equipped with a
DP71 microscope digital camera (Olympus), and the images
were captured using MicroSuite Basic Edition image analysis
software (Olympus America).
Treatment with adenoviruses
The adenoviruses expressing ATF3 (Ad.ATF3) and -galac-
tosidase (Ad.GLB1) were prepared by Chris Wolford (Ohio
State University, Columbus, Ohio) as previously described (29).
Preliminary experiments established the efficiency of adenoviral
transduction to be greater than 90%. Prior to adenovirus infec-
tion, the cells were preequilibrated with serum-free medium for
2 hours. Viral stocks were diluted in serum-free medium and
were added to the cells for 1.5 hours incubation. Cells were
incubated for an additional 20 hours with medium containing
10%FBS before further treatment. Initial experiments were per-
formed to determine viral titers needed for ATF3 expression.
Cell viability assays
MTTwas added to the media at a final concentration of 500
g/mL and after 3 hours incubation, theMTTworking solution
was removed. DMSO was added to dissolve the converted dye
and samples read at 570 nm using a SpectraMax Plus Spectro-
photometer. Caspase 3/7 activity was detected using a kit (Pro-
mega Corp.) following the manufacturer’s instructions and lu-
minescence was detected using a FLUOstar OPTIMA (BMG
LABTECH) plate reader. Cleaved-caspase 3 was detected by
Western blot.
In order to determine whether expression of ATF3 affected
cell survival signaling in response to IGF1, cells infected with
Ad.ATF3 or Ad.GLB1 were treated with IGF-1 (50 ng/mL) for
15 and 30 minutes, and Western blot was used to detect the
phosphorylation of AKT (Thr308) and AKT (Ser473).
CRE luciferase activity
To determine the effect of ATF3 on transcription driven by
the cAMP response element (CRE), we employed an adenoviral
CRE-driven luciferase (Luc) reporter construct (Ad.CRE-Luc
firefly luciferase), and the corresponding adenoviral control
constructs Ad.MCS-Luc (firefly luciferase) and internal control
construct Ad.pRL-Luc (Renilla luciferase). All of these adeno-
viral constructs were purchased from Vector Biolabs. Briefly,
cells were mixed with 2  106 pfu/mL of Ad.CRE-Luc plus
Ad.pRL-Luc or Ad.MCS-Luc plus Ad.pRL-Luc in serum-free
medium, after which cells were seeded into 48-well plates. FBS
(10% final concentration) was added to the media 1.5 hours
later, and cells were incubated overnight. The cells expressing
various Luc constructs were then infected with either Ad.ATF3
or Ad.GLB1 for 20 hours. Cells were then treated with control
media or LH for 4 hours. The Dual-luciferase reporter assay
system kit (Promega) was used to detect the luciferase signal
according to the manufacturer’s instructions. Briefly, cells were
washed with cold PBS, and passive lysis buffer was added to lyse
cells by shaking for 15 minutes. Lysates were transferred into
white opaque tissue culture plates (BD Biosciences), and LARII
(firefly luciferase) and STOP & GLO (Renilla luciferase) solu-
tions were added to read luminescence using a FLUOstar OP-
TIMA (BMG LABTECH) plate reader. The firefly luciferase
reporter activity was normalized to theRenilla luciferase signal.
Progesterone RIA
Cell culture-conditioned medium was collected for proges-
terone determination using a progesterone RIA kit (Diagnostic
Systems Laboratories, Inc) according to the manufacturer’s
instructions.
Statistical analysis
The data are presented as the means SEM. The differences
in means were analyzed by one-way ANOVA followed by
Tukey’s multiple comparison tests to evaluate multiple re-
sponses, or by t tests to evaluate paired responses. Two-way
ANOVA was used to evaluate repeated measures with Bonfer-
roni posttests to compare means. Statistical analysis was per-
formed using GraphPad Prism software from GraphPad Soft-
ware, Inc. *, P  .05; **, P  .01; ***, P  .001.
doi: 10.1210/me.2013-1274 mend.endojournals.org 2069
Results
PGF induces ATF3 mRNA and ATF3 protein
expression in vivo
To determine whether PGF could induce ATF3 expres-
sion in vivo, corpora lutea were collected from saline-in-
jected controls (0 hours) or 1, 2, and 4 hours after injection
with a luteolytic dose of a PGF analog. Very little ATF3
mRNAor ATF3 protein was detected in corpora lutea from
untreated control cows (Figure 1). Real-time PCR (Figure
1A) and in situ hybridization (Figure 1B) analysis revealed
that PGF increased ATF3 mRNA expression. The increase
in ATF3 mRNA was observed within 1 hour of treatment
(56-fold increase, P  .001) and remained elevated for at
least 240 minutes after treatment with PGF. ATF3 protein
was elevated within 1 hour following PGF treatment and
remained elevated after 4 hours of PGF treatment (Figure
1C). The expression and subcellular localization of ATF3 in
tissue samples were evaluated by immunohistochemistry.
Figure 1D shows representative immunostaining for ATF3
after PGF treatment comparedwith the control. Little ATF3
staining of the cytoplasm or nucleus was apparent in the
luteal tissues sections of saline-treated cows. In response to
PGF treatment, ATF3 was present in nuclei of LLCs. It ap-
peared that the nuclei of some of the SLCs were also stained
after 4 hours, but the nuclei of most other cell types (eg,
endothelial cells)werenot stained.A larger representationof
the immunostaining is provided as Supplemental Figure 1
published on The Endocrine Society’s Journals Online web
site at http://endo.endojournals.org.
PGF induces expression of ATF3
in LLCs
Bovine luteal cells were isolated
from corpora lutea obtained at the
midluteal phase and during early
pregnancy. PGF increased ATF3
within 1–2 hours after treatment in
luteal cells prepared from corpora
lutea of the midluteal phase (Figure
2A) and early pregnancy (Figure
2B). To further identify the cell type
responsible for the increase in ATF3
observed in response to PGF, SLCs
and LLCs were prepared by centrif-
ugal elutriation. Results showed
that PGF induced ATF3 expression
in mixed cell preparations and in
highly enriched preparations of
LLCs, but not in enriched prepara-
tions of SLCs (Figure 2C). The ex-
pression and subcellular localization
of ATF3 in isolated luteal cells
treated with PGF were also evalu-
ated by fluorescence immunocyto-
chemistry. ATF3 was expressed in
the nucleus after PGF treatment in
vitro (Supplemental Figure 2).These
results correspond well with the im-
munohistochemistry results show-
ing that ATF3 was expressed mostly
in the nucleus (Figure 1D).
Luteal cells are known to possess
receptors for and respond to TNF, a
cytokine implicated in luteal regres-
sion (39). TNF stimulates ATF3 ex-
pression in other cell types such as
Figure 1. PGF treatment in vivo induces ATF3 mRNA and ATF3 protein expression. Postpubertal
cattle of composite breeding were treated at midcycle with saline (n  3) or PGF (Lutalyse; n 
9). Ovariectomies were performed after 0, 1, 2, or 4 hours. A, Corpora lutea were processed for
RNA and ATF3 expression was measured by quantitative real-time PCR. Data are shown as
means  SEM. Statistical difference was determined by ANOVA followed by Tukey’s test. Bars
with different letters are significantly different, P  .001. B, Tissues were processed for in situ
hybridization to detect ATF3 mRNA (magnification, 200). 1) Control (CTL); 2) Treatment with
PGF for 1 hour; 3) Treatment with PGF for 4 hours; 4) GAPDH in Control. The mRNA is
represented as red dots. C, Corpora lutea were processed for protein to analyze ATF3 expression
by Western blot (upper panel). Quantitative analysis of the Western blot data is shown in the
lower panel. Results are shown as means 	 SEM of the ratio of ATF3 to GAPDH. Statistical
difference was determined by ANOVA and Tukey’s test. Bars with different letters are
significantly different, P  .001. D, Tissues were processed for immunohistochemistry to detect
ATF3 protein (black staining). White arrows indicate representative cells with positive ATF3
nuclear staining. 1) Control (CTL); 2) Treatment with PGF for 1 hour; 3) Treatment with PGF for 4
hours; 4) Negative control; ns, nonspecific staining. Scale bar, 100 m. ACTB, -actin.
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pancreatic -cells (40), C2C12mousemyoblast cells (41),
and human umbilical vein endothelial cells (32). We ob-
served that whereas only LLCs responded to PGF, both
SLCs and LLCs responded to TNF with significant in-
creases in ATF3 protein expression (Figure 2, D and E).
We also observed that TNF, but not PGF, stimulated
ATF3 expression in cultures of luteal endothelial cells
(Supplemental Figure 3).
PGF treatment in vitro induces temporal and
concentration-dependent increases in ATF3
expression and phosphorylation of MAPKs in LLCs
The temporal effects of PGF on ATF3 expression and
activation of MAPK signaling pathways were evaluated
in primary cultures of bovine LLCs (Figure 3A). ATF3
expression increased within 60 to 120 minutes following
treatment with PGF (100 nM) and remained elevated for
at least 240 minutes. PGF treatment also rapidly in-
creased the phosphorylation of the MAPK family mem-
bers including ERK1/2, JNK, and p38 MAPKs and their
downstream substrates JUN and HSP27 (Figure 3A).
ERK1/2 phosphorylation increased within 10 minutes
and remained elevated throughout the 240-minute incu-
bation with PGF. Maximal increases in JNK phosphory-
lation were observed as early as 10 minutes following
PGF treatment and then gradually decreased throughout
the 240-minute incubation. The phosphorylation of JUN,
a transcription factor and known target of JNK, increased
during the first 120 minutes of incubation and then re-
mained elevated throughout the remaining 120 minutes
of incubation with PGF. A rapid increase in p38 MAPK
phosphorylation was accompanied by an increase in the
phosphorylation of its downstream target HSP27.
To determine the concentration-dependent effects of
PGF on ATF3 expression and activation ofMAPK signal-
ing pathways, LLCs were treated with increasing concen-
trations of PGF for 120 minutes, a time point established
to provide near-maximal increases in ATF3 expression
(Figure 3A). We observed concentration-dependent in-
creases in ATF3 (Figure 3B) with as little as 1 nM PGF
stimulating increases in ATF3, and with 10–100 nM PGF
stimulating maximal increases in ATF3. Similar concen-
tration-dependent increases in the phosphorylation of
MAPK signaling components were also observed after
120 minutes of incubation (Figure 3B).
Contribution of MAPK signaling pathways to ATF3
expression in LLCs
Experiments were performed to evaluate whether the
inhibition of MAPK signaling would affect ATF3 expres-
sion in response to PGF. LLCs were pretreated for 1 hour
with inhibitors of MEK1/2 (U0126, 20 M), p38 MAPK
(SB203580, 2 M), or JNK (SP600125, 10 M), after
which cells were treated with PGF for 2 hours. Western
blot analysis showed that inhibitors of MEK1/2,
p38MAPK, and JNK, when used alone, did not signifi-
cantly reduce ATF3 expression (Figure 4A). However,
combinations of inhibitors were able to suppress ATF3
expression (Figure 4B), indicating that multiple converg-
ing signaling mechanisms involving several MAPKs may
Figure 2. PGF induces ATF3 expression in LLCs. Bovine luteal cells
prepared from the midluteal phase (A) and early pregnancy (B) were
treated with PGF (100 nM) for 10, 30, 60, 120, or 240 minutes after
which cells were processed for ATF3 expression by Western blot. -
Actin (ACTB) served as a loading control. C, Mixed luteal cells or highly
purified preparations of SLCs and LLCs were treated without (C) or
with PGF (P, 100 nM) for 2 hours and ATF3 expression was analyzed
by Western blot. D and E, SLCs and LLCs were treated without (C) or
with PGF (P, 100 nM), or TNF (T, 50 ng/mL) for 2 hours and ATF3
expression was analyzed by Western blot. E, Data are shown as
means  SEM from 3 experiments. Statistical difference was
determined by ANOVA and Tukey’s test. *, P  .05 vs CTL. CL,
corpora lutea; CTL, control.
Figure 3. Treatment with PGF induces time- and concentration-
dependent increases in ATF3 expression and phosphorylation of several
members of the MAPK family in LLCs. A, Bovine LLCs were treated
with PGF (100 nM) for 0–240 minutes. B, Bovine LLCs were treated
with 0–1000 nM PGF for 2 hours. Cell lysates were analyzed by
Western blot. -Actin (ACTB) was used a loading control. Data are
representative of 3 experiments.
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contribute to the induction of ATF3 by PGF in corpus
luteum.
ATF3 inhibits LH-stimulated progesterone but does
not alter the expression of key regulators of
progesterone synthesis
To explore the possible function of ATF3 in luteal
cells, we employed an adenovirus to express ATF3 in both
SLCs and LLCs. Experiments were performed to deter-
mine the effects of ATF3 on cell viability, progesterone
synthesis, and proteins involved in progesterone synthe-
sis. SLCs were infected with increasing amounts of
Ad.ATF3 and then treated with LH for 4 hours to stim-
ulate progesterone secretion. As shown in Figure 5, LH
significantly increased progesterone production in pri-
mary cultures of SLCs (fold increase: 21  3.7, mean 
SEM, n  3). Treatment with the control adenovirus ex-
pressing -galactosidase (Ad.GLB1) did not alter proges-
terone secretion under basal conditions or in response to
LH. Increasing the titer of Ad.ATF3 resulted in a concen-
tration-dependent increase in ATF3 expression as deter-
mined by Western blot (Figure 5). It also resulted in a
concentration-dependent reduction in LH-stimulated
progesterone production (% inhibition: 29  9, 65  9,
and 73 6, respectively, vs Ad.GLB1, mean SEM, n
3). Treatment with increasing titers of Ad.ATF3 did not
statistically reduce basal progesterone (% inhibition:
15 7, 31 12, and 28 12, respectively, vs Ad.GLB1,
mean  SEM, n  3).
Based on the foregoing results, we infected LLCs with
Ad.ATF3 prior to treatment for 4 hours with LH. LH
significantly increased progesterone production in LLCs
(6-fold increase, P  .01). Adenoviral-mediated expres-
sion of ATF3 significantly (P  .001) inhibited LH-stim-
ulated progesterone in LLCs (52  7% inhibition vs
Ad.GLB1, mean  SEM, n  3) (Figure 6).
Analysis was performed to determine whether the
ATF3-induced defect in LH-stimulated progesterone syn-
thesis was the result of a reduction in the expression of
proteins needed for delivery of cholesterol or the metab-
Figure 4. Effects of MAPK pathway inhibitors on PGF-induced ATF3
expression in LLCs. A, Bovine LLCs were pretreated with vehicle alone
(dimethylsulfoxide), MEK1 inhibitor U0126 (UO; 20 M), p38 inhibitor
SB203580 (SB; 2 M), JNK inhibitor SP600125 (SP; 10 M) for 60
minutes prior to treatment with PGF (100 nM) for 2 hours. B, LLCs
were pretreated with vehicle alone or combinations of U0126 (20 M),
SB203580 (2 M), SP600125 (10 M) for 60 minutes prior to
treatment with PGF (100 nM) for 2 hours. Cell lysates were analyzed
by Western blot. Data are shown as means  SEM from 3 or more
experiments. Statistical difference was determined by ANOVA followed
by Tukey’s test. *, P  .05. ns, nonsignificant, P  .05.
Figure 5. Adenoviral-mediated expression of ATF3 inhibits LH-
stimulated progesterone secretion in SLCs. Bovine SLCs were
transduced with 1  106 to 1  107 pfu/mL of adenoviruses
expressing ATF3 (Ad.ATF3) or -galactosidase (Ad.GLB1) as control.
After 20 hours the media were changed and cells were preequilibrated
with serum-free medium for 2 hours prior to treatment without
(Control) or with 100 ng/mL LH for 4 hours. The media were collected
for analysis of progesterone by RIA (upper panel). Cells were lysed and
proteins detected by Western blot analysis (lower panel). Results reflect
the findings in 3 separate experiments, each of which were performed
in triplicate. Statistical difference was determined by ANOVA and the
Tukey’s test. **, P  .01. ACTB, -actin.
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olism of cholesterol to progesterone. Western blot analy-
sis performed to determine levels of scavenger receptor
class B1 (SR-B1), hormone-sensitive lipase (also referred
to as LIPE), StAR, cytochrome P450 side-chain cleavage
(P450scc, CYP11A1), and HSD3B, and -actin as a load-
ing control revealed no changes in the expression of these
proteins in either SLCs (Figure 5) or LLCs (Figure 6) in
response to overexpression of ATF3.
Previous reports indicate that the induction of ATF3
may contribute to cell death (29, 30, 42). In order to
determine whether ATF3 expression also affected luteal
cell viability, SLCs and LLCswere infectedwith Ad.ATF3
or the control Ad.GLB1, and caspase activity and cell
viability assays were performed. As a positive control, we
observed that treatment with a combination of TNF, Fas
ligand, and cycloheximide effectively reduced cell viabil-
ity (Figure 7A), increased caspase 3/7 activity (Figure 7B),
and increased accumulation of the active cleaved-caspase
3 (Supplemental Figure 4A) within 24 hours. However,
neither Ad.ATF3 nor Ad.GBL1 altered cell viability,
caspase activity, or cleaved caspase 3 in SLCs or LLCs
after 24 or 48 hours. Furthermore, ATF3 expression did
not inhibit the stimulatory effect of IGF-1 on luteal cell
survival signals, such as the phosphorylation of AKT
(Ser308) and AKT (Thr473) (Supplemental Figure 4B).
Taken together, the data indicate that expression of ATF3
does not affect luteal cell viability.
Effect of ATF3 expression on LH-stimulated
protein kinase A (PKA) signaling and CRE-
mediated transcription
To determine whether treatment with Ad.ATF3 mod-
ified the early signaling response to LH, we used an anti-
body that detects the phosphorylation of PKA substrates
as a proxy for activation of the cAMP/PKA signaling
pathway. The phospho-PKA substrate (RRXphospho-
S/T) antibody detects proteins containing a phospho-ser-
ine or phospho-threonine residue with arginine at the3
and 2 positions (Cell Signaling Technology). Western
blot analysis showed that LH increased PKA phospho-
protein substrates harboring the PKA phosphorylation
motif in response to LH in both SLCs and LLCs (Supple-
mental Figure 5, A and B, respectively). However, the
expression of ATF3 did not alter the LH-stimulated in-
crease in PKA phospho-protein substrates.
ATF3 may repress or activate gene transcription
through formation of homodimers or heterodimers with
other members of the ATF/CREB family (43). We em-
ployed a CREB response element (CRE) luciferase-re-
porter expression system to determine whether ATF3
could alter LH-stimulated CRE-mediated transcription in
luteal cells. Luteal cells were infected with the reporter
adenovirus construct (Ad.CRE-Luc) or control luciferase
construct (Ad.MCS-Luc). As shown in Figure 8, LH sig-
nificantly increased CRE-dependent luciferase activity
both in SLCs (fold: 33  3.0, n  3) and LLCs (fold:
4.6  0.2, n  3), whereas it did not affect the control
(MSC-Luc) luciferase activity. Importantly, we ob-
served that expression of ATF3 significantly inhibited
the LH-driven CRE-dependent transcription (% inhi-
bition: 34  2.1 in SLCs and 30  5 in LLCs vs
Ad.GLB1; mean  SEM, n  3).
ATF3 does not inhibit progesterone production in
the presence of 22R-hydroxycholesterol
Because our studies did not show a reduction in known
sterol transport proteins or enzymes that convert choles-
terol to progesterone, we performed an experiment to
determine whether the ATF3-induced reduction in pro-
gesterone was due to a reduction in activity of the en-
zymes required to convert cholesterol into progesterone.
Both SLCs and LLCs were infected with Ad.ATF3 or the
Figure 6. Adenoviral-mediated expression of ATF3 inhibits
progesterone secretion in LLCs. Bovine LLCs were transduced with 5 
106 pfu/mL adenovirus expressing ATF3 (Ad.ATF3) or -galactosidase
(Ad.GLB1) as control. After 20 hours the media were changed and
cells were preequilibrated with serum-free medium for 2 hours prior to
treatment without (Control) or with 100 ng/mL LH for 4 hours. The
media were collected for analysis of progesterone by RIA (upper
panel). The cells were lysed and proteins detected by Western blot
analysis. Results reflect the findings in 3 separate experiments, each of
which was performed in triplicate. Statistical difference was
determined by ANOVA and the Tukey’s test. ***, P  .001. ACTB,
-actin.
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control adenovirus Ad.GLB1 as described previously, and
then treated with 22R-hydroxycholesterol (22R-OH-
CH), a membrane-permeable cholesterol. We observed
that treatment with 22R-OH-CH significantly increased
progesterone production in SLCs (fold increase: 6.7 2.2
after 4 hours, n  4) and LLC (fold increase: 2.0  0.6
after 4 hours, n  4). Importantly, the ability of 22R-
OH-CH to increase progesterone was not interrupted by
prior expression of ATF3 (Figure 9) in either LLCs or
SLCs. Although ATF3 did not inhibit 22R-OH-CH-stim-
ulated progesterone production in either cell type, in this
set of experiments ATF3 expression effectively inhibited
LH-stimulated progesterone production in SLCs by 67
6.1% after treatment for 4 hours (Figure 9A) and by 73
6.0% after 24 hours. In LLCs, ATF3 inhibited LH-stim-
ulated progesterone production by 36  4.6% after 4
hours (Figure 9B).
Discussion
Prostaglandin F2 initiates several signaling pathways in
the corpus luteum, including elevations in intracellular
calcium and activation of protein ki-
nase C and MAPK signaling cas-
cades (4–8). The PGF-induced
changes in intracellular signaling
culminate in the regulated expres-
sion of many genes in the corpus lu-
teum (11, 34). A number of immedi-
ate early genes, including FOS, JUN,
EGR1, and ATF3, have been identi-
fied but their role in PGF-induced
luteolysis remains unclear (2, 9, 11,
13). In this study we report that PGF
induces the expression of ATF3
mRNA and ATF3 protein in the
LLCs of the bovine corpus luteum in
vivo. The effect of PGF onATF3was
limited to the LLCs in vitro, whereas
the cytokine TNF induced ATF3 in
both LLCs and SLCs. Overexpres-
sion of ATF3 in either LLCs or SLCs
resulted in impaired progesterone
secretion in response to LH. We
hypothesize that the induction of
ATF3 serves to modulate gona-
dotropin responsiveness during
luteolysis.
The corpus luteum of most mam-
mals is composed of multiple, dis-
tinctive cell types including steroid-
ogenic cells (SLCs and LLCs) and
nonsteroidogenic cells (endothelial cells, pericytes, fibro-
blasts, and immune cells). Endothelial cells are thought to
represent about 50% of the cells in the mature bovine
corpus luteum, with steroidogenic cells representing 40%
and the remaining cell types about 10%. The large ste-
roidogenic luteal cells possess most receptors for PGF
(PTGFRs) whereas small steroidogenic cells have few PT-
GFRs (44). Recent studies provide evidence that endothe-
lial cells may also possess the PTGFR (38, 45). Our data
shows that ATF3 expressionwas very low to undetectable
in luteal tissue from midluteal-phase cows and that PGF
treatment in vivo rapidly induced the expression of ATF3
mRNA and ATF3 protein in LLCs. The size and limited
number of cells responding to PGF indicates that most
SLCs and endothelial cells did not express ATF3 for up to
4 hours following treatment with PGF. The cell-specific
induction of ATF3 in response to PGF in the LLCs in vivo
was also observed in vitro using highly purified prepara-
tions of luteal cells, in which LLCs, but neither SLCs nor
corpus luteum-derived endothelial cells responded to PGF
with an increase in ATF3. The lack of effect of PGF on
endothelial cells derived from the bovine corpus luteum is
Figure 7. Expression of ATF3 does not affect viability of LLCs or SLCs. Bovine SLCs and LLCs
were transduced with 5  106 pfu/mL adenovirus expressing ATF3 (Ad.ATF3) or -galactosidase
(Ad.GLB1) as described in Figure 6. Cells were treated with TNF (50 ng/mL) 	 FasL (100 ng/mL)
	 Cycloheximide (Cx, 10 g/mL) for 24 hours and 48 hours as a positive control for indices of
cell death. MTT cell viability assays (A) and caspase 3/7 activity assays (B) were performed as
described in Materials and Methods. Data are shown as means  SEM from 3 experiments.
Statistical difference was determined by ANOVA followed by Tukey’s multiple-range test. *, P 
.05; **, P  .01; ***, P  .001 vs control (CTL). FasL, Fas ligand.
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consistent with the work of others (35, 46). The temporal
increase in ATF3 observed in vivo following PGF treat-
ment was mimicked in LLCs following PGF treatment in
vitro. Furthermore, our studies showed that increases in
ATF3 expression were observed at 1 nM PGF (0.3 ng/
mL) with maximal increases observed at 10–100 nM
PGF. These findings are in keeping with the established
Kd for PGF binding to its receptor (47) and concentra-
tions of PGF reported in the pulses of PGF (0.6–11 ng/ml)
that reach the ovary (39, 48) during spontaneous luteal
regression. Collectively, our findings demonstrate that
the LLCs of the corpus luteum respond to PGF with an
increase in ATF3 expression.
Although ATF3 is generally held to be a stress-induc-
ible gene (29, 49), it is also responsive to hormones and
environmental cues (50–52). The signaling mechanisms
involved in induction of ATF3 are incompletely charac-
terized; however, activated MAPK pathways have been
implicated in the induction of ATF3 expression. The pro-
moter region of the human ATF3 gene contains binding
sites for a number of transcription factors, including ac-
tivator protein-1, ATF/CRE, NFB, E2F, MYC/MAX,
EGR1, CCAAT enhancer binding protein, and SMAD
proteins (20, 52, 53). Binder et al (50) found that GnRH,
a ligand that activates a Gq-coupled receptor, specifically
regulates ATF3 mRNA in murine LT2 cells through a
pathway that includes intracellular Ca2	, calcineurin,
JNK, and nuclear factor of activated T cells. Lu et al (54)
found that the p38MAPK pathway plays a critical role in
the induction of ATF3 by stress signals, and that ATF3 is
functionally important to mediate the proapoptotic ef-
fects of p38MAPK, whereas the ERK and JNK signaling
pathways are neither necessary nor sufficient to induce
ATF3 in the anisomycin-induced stress paradigm. A re-
port by Sandnes et al (55) showed that although inhibi-
tion of each of the MAPKs ERK1/2, JNK, or p38 did not
affect vasopressin-induced ATF3 expression in hepato-
cytes, the combined inhibition of JNK and p38, and of
ERK1/2 and either JNK or p38 suppressed vasopressin-
induced expression of ATF3 in hepatocytes. In the present
study, we found that PGF stimulates ERK1/2, p38, and
JNK MAPK signaling pathways in bovine LLCs and that
selective inhibition of ERK1/2, p38, and JNK signaling
had very little effect on PGF-induced ATF3 expression.
However, combinations ofMAPK inhibitors significantly
inhibited the stimulatory effect of PGF on ATF3 expres-
sion in LLCs. Although these results do not preclude the
involvement of other Ca2	 and/or PKC-dependent signal-
ing pathways, the MAPKs appear to contribute to the
induction of ATF3 in a partly redundant manner in bo-
vine LLCs. Whether other recently described PGF-in-
duced signaling components, such as reactive oxygen spe-
cies and NFB activation, contribute to ATF3 expression
in the corpus luteum requires further investigation (56).
ATF3 has been implicated in cell context-specific re-
sponses involving cellular proliferation (57), survival
(58), and apoptosis (42, 59). In a study to determine the
expression of genes involved in the luteolytic response to
PGF, Mondal et al (34) found that PGF treatment in-
creased ATF3 protein expression in bovine corpora lutea
collected during the midluteal phase (day 11), but not in
the early luteal phase (day 4), althoughATF3mRNAwas
abundant on day 4. This result is intriguing because the
corpora lutea of both early- and midluteal phases possess
PTGFR (45) and respond to PGF with rapid changes in
gene expression, but the early luteal phase corpora lutea
do not undergo luteolysis when challenged by PGF. This
suggests that the ability of PGF to induce ATF3 expres-
sion could be required for luteal regression. Our observa-
tion that adenoviral-mediated expression of ATF3 re-
duced luteal progesterone synthesis supports this idea.
However, our data also suggest that expression of ATF3
does not affect the induction of caspase activity or the
viability of SLCs or LLCs. Therefore, it seems clear that
Figure 8. Expression of ATF3 inhibits LH-stimulated CRE-dependent
transcription. Bovine SLCs and LLCs were mixed with Ad.MCS-Luc plus
Ad.pRL-Luc, or Ad.CRE-Luc plus Ad.pRL-Luc (2  106 pfu/mL) and
incubated overnight. The cells were then infected with either Ad.GLB1
or Ad.ATF3 (5  106 pfu/mL) for an additional 20 hours. After
preequilibration, SLCs or LLCs were treated without (Control) or with
LH (100 ng/mL) for 4 hours. A Dual-Luciferase reporter assay system
was used to detect the luciferase activity. Each experiment was
performed in triplicate, and 3 separate experiments were performed.
Data are shown as means  SEM from 3 experiments. Statistical
difference was determined by ANOVA and the Tukey’s test. ***, P 
.001.
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ATF3 expression is not sufficient to induce apoptosis in
steroidogenic cells. It is of interest to note that the ability
of PGF to stimulate ATF3 expression wasmuch greater in
vivo when compared with in vitro results with isolated
luteal cells in culture. The reasons for the differential re-
sponses are not clear but could reflect a loss of cellular
responsiveness to PGF during cell isolation and the exper-
imental conditions in vitro. It is also conceivable that
optimal PGF responsiveness requires preservation of the
existing 3-dimensional luteal architecture in vivo and the
rapid activation of additional signaling molecules. It is
appreciated that other factors like endothelins, angioten-
sin, and cytokines contribute to luteal regression in re-
sponse to PGF (16, 17, 60, 61). That a combination of
ligands could influence ATF3 expression is supported by
our experiments indicating that a TNF, a cytokine known
to influence luteal regression (62–65), stimulated ATF3
expression in LLCs and SLCs and endothelial cells.
ATF3 regulates transcription in a cell-specific manner,
providing both stimulatory and inhibitory influences on
gene transcription (43). The ATF/CRE-binding protein
(CREB) family of transcription factors binds as dimers to
a basic zipper (bZIP) DNA-binding domain with a 5-
TGACGTCA-3 recognition sequence. ATF3 inhibits
CREB binding to CRE sites and in-
hibits CRE-mediated transcription
(28, 66, 67). Our experiments to de-
termine whether ATF3 contributes
in a functional way to luteal regres-
sion showed that overexpression of
ATF3 significantly inhibited LH-
stimulated, but not basal, progester-
one production by both SLCs and
LLCs. The inhibitory effect of ATF3
did not appear to alter the early sig-
naling effects of LHbecause the abil-
ity of LH to increase the phosphor-
ylation of protein kinase A (PKA)
substrates was not reduced by
ATF3. However, overexpression of
ATF3 significantly reduced the abil-
ity of LH to stimulate CRE-medi-
ated gene transcription as shown in
experiments using a CRE-driven lu-
ciferase reporter. The inhibitory ef-
fects of ATF3 on LH-stimulated
CRE-mediated transcription and
progesterone synthesis were not as-
sociated with alterations in the ex-
pression of proteins important for
cholesterol import (SRB1), mobili-
zation and transport of cholesterol
(LIPE, StAR), or conversion of cholesterol to progester-
one (CYP11A and HSD3B). Furthermore, the activity of
CYP11A and HSD3B in LLCs and SLCs was largely un-
affected by ATF3 because the conversion of an exogenous
source of cholesterol (22R-hydroxy cholesterol) to pro-
gesterone was similar in control and ATF3-expressing
cells. Grusenmeyer and Pate (68) reported that the inhib-
itory effects of PGF on lipoprotein-stimulated progester-
one production did not involve a reduction in cellular
uptake of cholesterol nor conversion of 25-hydroxycho-
lesterol to progesterone, suggesting an inhibition of a site
subsequent to cholesterol entry into the cell but before
mitochondrial cholesterol side-chain cleavage. Similar
findings were reported by Wiltbank et al (69) who found
that protein kinase C-mediated inhibition of progesterone
synthesis in ovine LLCs was not observed when treated
with 20-OH-, 22-OH-, or 25-OH-cholesterol derivatives.
Because 22R-hydroxy cholesterol bypasses the first of 3
reactions mediated by the side chain cleavage enzyme
CYP11A (70, 71), it is possible this initial step may be
indirectly targeted by ATF3. Consequently, ATF3 ap-
pears to affect gonadotropin-stimulated progesterone se-
cretion at a step or steps downstream of PKA signaling
and before cholesterol conversion to progesterone.
Figure 9. ATF3 inhibits LH but not 22-hydroxy-cholesterol (22OHCH)-induced progesterone
synthesis. Bovine SLCs (panel A) and LLCs (panel B) were infected with Ad.GLB1 or Ad.ATF3 (5 
106 pfu/mL) for 20 hours. After equilibration, the cells were treated without (control [CON]) or
with LH (100 ng/mL) or 22OHCH (20 M) for 4 hours. Progesterone in conditioned medium was
measured by RIA. Each experiment was performed in triplicate, and 4 separate experiments were
performed. Data are shown as means  SEM of the amount of progesterone in the medium (left
panel) and as the amount of progesterone after expressing the data relative to the control
response (Ad.GLB1) in each experiment (right panel). Statistical difference was determined by
two-way ANOVA, followed by Tukey’s testing for differences in the means. **, P  .01. ns,
nonsignificant (P  .05).
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